<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">08280</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2019.08280</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Was ist Ihre Diagnose?</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Endokrinologie / Diabetologie und Stoffwechsel </subject>
          <subject>Labormedizin</subject>
          <subject>Onkologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Une hypokaliémie sévère et réfractaire</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Basbous</surname>
            <given-names>Mohamed</given-names>
          </name>
          <email>basbous.mohamed@gmail.com</email>
          <aff>médecine interne | Rue du Bugnon 46 | Lausanne | 1011 | SWITZERLAND | +41 76 570 71 09</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Papadakis</surname>
            <given-names>Georgios</given-names>
          </name>
          <email>Georgios.Papadakis@chuv.ch</email>
          <aff>CHUV, service d'endocrinologie, diabétologie et métabolisme</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Lamine</surname>
            <given-names>Faiza</given-names>
          </name>
          <email>Faiza.Lamine@chuv.ch</email>
          <aff>CHUV, service d'endocrinologie, diabétologie et métabolisme</aff>
        </contrib>
        <contrib id="author-4" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Tagan</surname>
            <given-names>Damien</given-names>
          </name>
          <email>damien.tagan@hopitalrivierachablais.ch</email>
          <aff>Service des soins intensifs, hôpital riviera chablais, site du Samaritain, Vevey</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="will-be" iso-8601-date="2019.09.25">
        <day>25</day>
        <month>09</month>
        <year>2019</year>
      </pub-date>
      <volume>19</volume>
      <issue>3940</issue>
      <fpage>651</fpage>
      <lpage>654</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2019</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">&lt;p&gt;*	Une hypokaliémie sévère associée à une alcalose métabolique peut être la manifestation inaugurale d'un syndrome de Cushing. D'autres symptômes et signes cliniques d'hypercortisolisme doivent être recherchés devant cette association. 

*	En phase aiguë, en présence d'un syndrome de Cushing sévère, la priorité est la correction des perturbations électrolytiques, le contrôle des atteintes métaboliques, la recherche active des complications infectieuses et la prophylaxie des maladies thromboemboliques. 

*	Un traitement spécifique de métyrapone à dose efficace permet généralement un contrôle rapide de la cortisolémie et par conséquent une amélioration rapide des complications électrolytiques de l'hypercorticisme.&lt;/p&gt;</abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
